A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Paragonix Technologies Announces Commercial Availability of the FDA-cleared BAROguard™ Donor Lung Preservation System Nationwide

The innovative airway management device for donor lungs is now commercially available for use in clinical transplantation across the United States to promote maximum control over preservation conditions throughout procurement

BAROguard™ Donor Lung Preservation System

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard ™ Donor Lung Preservation System. After an overwhelmingly positive response and demand during its limited market release, the technology is now available to transplant centers and Organ Procurement Organizations across the United States.

Clinically Proven Hypothermic Preservation Techniques

First-of-its-kind, the novel BAROguard system combines clinically proven hypothermic preservation techniques alongside active airway management control to ensure that donor lungs maintain optimal conditions during transport for maximum protection. Equipped with built-in tracking and real-time reporting, the device provides surgeons and transplant teams with continuous data on the organ’s condition throughout transit.

FDA Clearance Secured

Paragonix Technologies received FDA 510(k) clearance for the device in August 2023, and conducted its first-in-human case at Duke University Medical Center in November 2023. Throughout its limited market release, five of the country’s top thoracic transplant centers (Duke Health, Massachusetts General Hospital, Johns Hopkins Medicine, UCSF Health, UCLA Health) deployed the BAROguard System to safely place donor lungs for lung transplantation.

Dr. Nathaniel Langer, MD, MSC, Surgical Director, Lung Transplantation at Massachusetts General Hospital

“Traditional lung preservation does not provide transplant teams with any information about the actual conditions experienced by the organ. Unlike any other organ, lungs must hold air, so they are susceptible to damage from both over and under inflation during transport. The introduction of a device that both actively manages airway pressure and provides real-time data on internal temperature+- conditions during transport is an exciting advance that I hope will increase the availability of quality donor lungs to transplant programs around the country.”

The highly anticipated device launches in advance of the 44th ISHLT (International Society for Heart and Lung Transplantation) Annual Meeting and Scientific Sessions, where it is available for demonstrations at the Paragonix exhibit at the Prague Congress Centre in Prague, Czech Republic, from April 10th to April 13th. Attendees will have the opportunity to examine the new technology and hear from leading clinical experts who participated in the limited market release, such as Dr. Jasleen Kukreja, director of the Lung Transplant Program at UCSF Medical Center. Dr. Kukreja joins a panel of esteemed preservation experts on Friday, April 12th, to lead an industry symposium entitled “Reimagined Clinical Standards: Transformative Innovations in Organ Preservation,” which will feature research showcasing the impact of the BAROguard System’s active pressure control.

Dr. Lisa Anderson, CEO and President of Paragonix Technologies

“The commercial launch of BAROguard represents a significant breakthrough for the organ transplantation industry. We are immensely pleased with the success it has already achieved, and we are excited to offer this game-changing technology nationwide to help transplant surgeons and their teams to innovate the standard of care in transplantation.”

The valuable data collected from the commercial use of the BAROguard device will contribute to the renowned GUARDIAN-Lung study, a post-market observational registry intended to evaluate the clinical outcomes of patients who have donor lungs preserved with Paragonix lung preservation devices versus other storage methods.


The BAROguard System is available for clinical use across the United States. For more information about Paragonix Advanced Organ Preservation devices, please visit www.paragonix.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy